Diphenylether

Diphenylether

SCHEMBL4265157

N.c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 7/20 0.92
TSHR P16473 1/20 0.92
NR1H2 P55055 1/20 0.63
BAX Q07812 1/20 0.63
MAOA P21397 1/20 0.63
CA1 P00915 2/20 0.55
CA2 P00918 2/20 0.55
MAOB P27338 1/20 0.55
GSTP1 P09211 1/20 0.50
SOS1 Q07889 1/20 0.50
CA9 Q16790 1/20 0.50
PARP10 Q53GL7 1/20 0.50
PLA2G2A P14555 1/20 0.50
CA4 P22748 1/20 0.50
MEN1 O00255 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 1/20 0.48
NLRP3 Q96P20 1/20 0.48
SRD5A2 P31213 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylether SCHEMBL179902 1.00 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL28009593 0.96 LTA4H (0.86) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL12286 0.96 LTA4H (1.00) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL2461810 0.96 LTA4H (1.00) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL9061108 0.96 LTA4H (1.00) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL4950525 0.96 LTA4H (1.00) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL10621546 0.92 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL2886896 0.92 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
Diphenylether SCHEMBL11777679 0.92 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA
SCHEMBL22129853 0.92 LTA4H (0.92) LTA4HTSHRNR1H2BAXMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11161818-B2 Quinolone derivatives, preparation methods and application thereof HANGZHOU NORMAL UNIVERSITY (CN) 2021-11-02 US claimed
US-20210198207-A1 QUINOLONE DERIVATIVES, PREPARATION METHODS AND APPLICATION THEREOF HANGZHOU NORMAL UNIVERSITY (CN) 2021-07-01 US claimed
CN-111018778-B Quinolone derivative and preparation method and application thereof 杭州师范大学 2020-11-06 CN claimed
CN-111018778-A Quinolone derivative and preparation method and application thereof 杭州师范大学 2020-04-17 CN claimed
CN-107344731-B A kind of preparation method of the water-soluble Superparamagnetic Fe3O4 nanoparticles of single layer cladding 南京大学 2019-06-21 CN claimed
CN-107344731-A A kind of preparation method of the water-soluble SPIO of individual layer cladding 南京大学 2017-11-14 CN claimed
CN-106519217-A Method for preparing polyamide graft-modified halogen-free flame retardant through reactive extrusion 扬州赛尔达尼龙制造有限公司 2017-03-22 CN claimed
CN-103930095-A Eutectic mixture for pulmonary administration PROSONIX LTD 2014-07-16 CN claimed
CN-103648488-A Pharmaceutical compositions and use in treating cough conditions BIOCOPEA LTD 2014-03-19 CN claimed
CN-102753174-A Pharmaceutical combinations of theobromine and their use in therapy BIOCOPEA LTD 2012-10-24 CN claimed
US-5340905-A Using a quaternary ammonium or phosphonium compound as catalyst BAYER AKTIENGESELLSCHAFT (DE) 1994-08-23 US claimed
US-20240282503-A1 MAGNETIC PARTICLES, DUST CORE, AND COIL COMPONENT MURATA MANUFACTURING CO., LTD. (JP) 2024-08-22 US disclosed
US-20240240043-A1 INKJET PRIMER COMPOSITIONS U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2024-07-18 US disclosed
US-20240228805-A1 INKJET PRIMER COMPOSITIONS CONTAINING NANOCELLULOSE U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2024-07-11 US disclosed
EP-4397728-A1 INKJET PRIMER COMPOSITIONS CONTAINING NANOCELLULOSE Xerox Corporation (US) 2024-07-10 EP disclosed
US-5340905-A Using a quaternary ammonium or phosphonium compound as catalyst BAYER AKTIENGESELLSCHAFT (DE) 1994-08-23 US disclosed
US-4830850-A CONDITIONERS, SOFTENERS, PRESERVATIVES GAF CORPORATION (US) 1989-05-16 US disclosed
US-4287052-A FOR BENEFICIATING SILICEOUS MINERAL ORES THE DOW CHEMICAL COMPANY (US) 1981-09-01 US disclosed
US-4287052-A FOR BENEFICIATING SILICEOUS MINERAL ORES THE DOW CHEMICAL COMPANY (US) 1981-09-01 US disclosed
US-4287052-A FOR BENEFICIATING SILICEOUS MINERAL ORES THE DOW CHEMICAL COMPANY (US) 1981-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11161818-B2 Quinolone derivatives, preparation methods and application thereof NQO2, MRPL21, TOP1 LTA4H 2366/4885TSHR 4650/4885NR1H2 2348/4885
US-20210198207-A1 QUINOLONE DERIVATIVES, PREPARATION METHODS AND APPLICATION THEREOF NQO2, MRPL21, TOP1 LTA4H 2366/4885TSHR 4650/4885NR1H2 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.